Clinical Trial Update: Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab [Phase 2]

View source ↗

Summary

Pfizer's Phase 2 study evaluating the long-term safety and efficacy of subcutaneous bapineuzumab in Alzheimer's disease was terminated, with results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Bapineuzumab (bapineuzumab)

Snippet

Sponsor: Pfizer | Conditions: Alzheimer Disease | Phase 2 | Status: TERMINATED | Results posted: 2017-06-01